Dr Chris Sheldon
Chris has worked in the UK at AstraZeneca (AZ) for over 15 years and is currently Head of Oncology Search & Evaluation in AZ’s Strategy team in its Oncology Business Unit (OBU). Chris and his team are responsible for scouting of new oncology technologies and leading the technical evaluation of new M&A, in-licensing, out-licensing (divestment) and collaboration opportunities in clinical stage oncology. Most recently, he led the evaluation of AstraZeneca’s recent majority $4 billion stake investment in Acerta Pharma for Calquence (acalabrutinib), as well as multiple novel immuno-oncology combination deals for AstraZeneca’s immune checkpoint inhibitor Imfinzi (durvalumab), including a recently announced Phase III collaboration with Incyte.
Prior to this Chris worked in early stage oncology business development and was involved in all aspects of evaluation, due diligence and negotiation of deals. Before his business development career, Chris worked in discover research at AstraZeneca as a senior research chemist. He also holds a Ph.D. in chemistry from the University of Bristol, UK and a first class honours degree from the University of Sheffield, UK.